Deta yatsopano yamankhwala oletsa ma virus a Hepatitis B ndi C

Sayansi ya Gileadi lero yalengeza zambiri kuchokera ku maphunziro angapo omwe akuwonetsa phindu lachipatala ndi kusiyanitsa kwa chithandizo cha matenda a chiwindi, komanso kudzipereka kosalekeza kwa Gileadi pa kafukufuku wa chiwindi kuti apititse patsogolo kuthetsa matenda a hepatitis ku Asia. Zambirizi zikuperekedwa ku Msonkhano wa 31st wa Asia Pacific Association for the Study of the Liver (APASL 2022), March 30 - April 3, 2022 ku Seoul, South Korea.    

"Zomwe zapezeka m'maphunziro athu zimatsimikizira momwe chithandizo chathu chimathandizira komanso chitetezo chamankhwala athu komanso phindu lomwe lingakhalepo kwa anthu omwe ali ndi matenda a chiwindi a B ndi C. Zambiri zolimbikitsazi zitha kuthandiza othandizira azaumoyo kupanga chisankho choyenera kwa odwala matenda a chiwindi. ku Asia.” adatero Betty Chiang, Wachiwiri kwa Purezidenti wa Medical Affairs, International, Gilead Sciences.

Deta yochokera ku maphunziro atatu a tenofovir (TFV) okhudzana ndi matenda a chiwindi a B (HBV) omwe adaperekedwa pamsonkhanowo adawonetsa kuti pakuyambika kwamankhwala odwala ochepa omwe ali pachiwopsezo chochepa cha hepatocellular carcinoma (HCC) adapita patsogolo kukhala pachiwopsezo chachikulu, pomwe ambiri apakati kapena apamwamba. -odwala omwe ali pachiwopsezo adasintha kuti achepetse chiopsezo cha HCC pambuyo pa chithandizo chanthawi yayitali cha TFV.  

Deta yochokera ku kafukufuku wa Phase 2 wa TFV disoproxil fumarate (TDF) vs. TDF/emtricitabine (FTC) mwa odwala omwe ali ndi chitetezo chamthupi (IT) ndi maphunziro awiri a Phase 3, kuyerekeza tenofovir alafenamide (TAF) vs. TDF mu immune-active (IA) ) odwala adagwiritsidwa ntchito kuti apange ziwopsezo za HCC pogwiritsa ntchito Modified PAGE-B (mPAGE-B), chida chodziwiratu chiopsezo cha HCC chazaka 5 (chiwopsezo chochepa [0-≤8], chiwopsezo chapakati [9-12], ndi chiopsezo chachikulu [≥13]). 

Mwa odwala 126 a IT, 106 (84%), 19 (15%) ndi 1 (0.8%) anali otsika, apakatikati, kapena pachiwopsezo chachikulu, motsatana. Pa Sabata 192, ambiri adakhalabe osasintha kapena kusintha. Palibe odwala a IT omwe adapanga HCC. Odwala a 1,631 IA (1,092 TAF; 539 TDF-> TAF), 901 (55%), 588 (36%), ndi 142 (9%) anali otsika-, apakati-, kapena oopsa kwambiri, motsatira poyambira. Pa Sabata 240, ambiri adakhalabe osasintha kapena kuwongolera; Odwala a 22 (2%) okha ndi omwe adasamukira ku chiopsezo chachikulu. Ponseponse, milandu ya 22 HCC idapangidwa (0.2%, 1.2%, ndi 9.2% m'magulu otsika, apakatikati, ndi omwe ali pachiwopsezo choyambira).

Zambiri zomwe zaperekedwa pamsonkhanowu zimapereka kuwunika kwachitetezo cha mafupa ndi aimpso a TAF kudutsa pulogalamu yachitukuko yachipatala ya TAF HBV ya Gileadi. Zambiri kuchokera kwa odwala 1,911 omwe amathandizidwa ndi TAF kapena TDF adawunikidwa ndi mitundu ingapo ya odwala a HBV, kuphatikiza omwe ali pachiwopsezo chachikulu cha mafupa okhudzana ndi TDF ndi / kapena poizoni wa aimpso. Zokhazikika kapena zosinthika za mafupa ndi aimpso zidawonedwa ndi chithandizo cha TAF poyerekeza ndi chithandizo cha TDF.

Mu matenda a hepatitis C, kafukufuku wa Phase 3b wowona odwala omwe ali ndi matenda a chiwindi C (CHC) ku Korea adawonetsa kuti chithandizo cha sofosbuvir/velpatasvir ndi sofosbuvir/velpatasvir/voxilaprevir chinakwaniritsa kuyankha kwamphamvu kwa virological popanda ma virologic. kulephera kapena zochitika zazikulu zokhudzana ndi chithandizo. Mu kafukufuku wina wowunika momwe angagwiritsire ntchito mankhwala osokoneza bongo (DDIs) mwa odwala a CHC aku Korea omwe amagwiritsa ntchito ma antivayirasi omwe amapezeka kwambiri, sofosbuvir/velpatasvir adawonetsa mbiri yabwino ya DDI ngakhale kuchuluka kwa comorbidity ndi nthabwala pakati pa ukalamba wa anthu a CHC ku Korea.